Conference call - RSV Phase 1 Results
May 23, 2016 | Investor
The management of Bavarian Nordic hosted a conference call to discuss the Phase 1 results for MVA-BN RSV followed by a Q&A session.
MENU
- About us
ABOUT US
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
READ MORE - Pipeline
PIPELINE
Our pipeline comprises multiple product candidates which are subject to more than 20 ongoing clinical studies in infectious diseases and cancer. Many of our programs are supported by external funding through either private or governmental partnerships.
Read more - INVESTORS
INVESTORS
Bavarian Nordic is committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Read more - Careers
CAREERS
Bavarian Nordic offers a challenging international working environment in which
READ MORE
job satisfaction and personal growth have a high priority.